Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 16/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3941792 | 0.93 | P2RY12 (0.58) | P2RY12ALDH1A1CHRM2CYP3A4CYP2C9 | |
| SCHEMBL3930786 | 0.90 | P2RY12 (0.47) | P2RY12ALDH1A1CHRM2CYP3A4CYP2C9 | |
| SCHEMBL3930016 | 0.83 | KDM4E (0.59) | P2RY12ALDH1A1KDM4EMAPT | |
| SCHEMBL4173356 | 0.83 | P2RY12 (0.69) | P2RY12ALDH1A1CHRM2CYP3A4CYP2C9 | |
| SCHEMBL3930910 | 0.82 | P2RY12 (0.57) | P2RY12ALDH1A1CHRM2CYP3A4CYP2C9 | |
| SCHEMBL4356065 | 0.82 | ALDH1A1 (0.55) | P2RY12ALDH1A1CYP3A4CYP2C9KDM4E | |
| SCHEMBL4365314 | 0.81 | P2RY12 (0.64) | P2RY12ALDH1A1KDM4EMAPT | |
| SCHEMBL3936151 | 0.78 | P2RY12 (0.56) | P2RY12ALDH1A1KDM4EMAPT | |
| SCHEMBL4351349 | 0.77 | P2RY12 (0.59) | P2RY12ALDH1A1KDM4EMAPT | |
| SCHEMBL3590489 | 0.76 | P2RY12 (0.82) | P2RY12CHRM2CYP3A4CYP2C9DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286834-A1 | Pyridine Analogues VI | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | claimed |
| US-20080045494-A1 | Pyridine Analogues VI | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | claimed |
| US-20090286834-A1 | Pyridine Analogues VI | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
| EP-2044024-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080045494-A1 | Pyridine Analogues VI | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| WO-2008004943-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045494-A1 | Pyridine Analogues VI | P2RY12, P2RY6, P2RY11 | P2RY12 1/4885ALDH1A1 1604/4885CHRM2 463/4885 |
| US-20090286834-A1 | Pyridine Analogues VI | P2RY12, P2RY6, P2RY11 | P2RY12 1/4885ALDH1A1 1888/4885CHRM2 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.